概括
在COVID-19患者中,治疗性氨酸的使用增加了出血和氨酸诱导的血栓缩 (HIT). 疫苗诱发的免疫血栓性血栓性缺血症 (VITT) 与HIT有相似之处,需要非肝素抗凝剂进行治疗.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 临界护理医学 临界护理医学
背景情况:
- 对COVID-19患者广泛使用治疗性氨酸增加了出血和氨酸诱导的血小板缩 (HIT).
- COVID-19疫苗 (AstraZeneca,约翰逊和约翰逊) 与疫苗诱导的免疫血栓性血栓性缺血症 (VITT) 有关,这是一个严重的血栓性并发症.
- 在临床和病理生理上,VITT与HIT具有相似之处,HIT是一种免疫介导的不良药物反应.
研究的目的:
- 突出COVID-19中治疗性肝素相关的出血和HIT发生率增加.
- 讨论VITT作为COVID-19疫苗接种后罕见但严重的不良事件的出现和特征.
- 强调HIT和VITT之间的临床和病理生理学相似之处.
主要方法:
- 对临床数据和关于重症COVID-19患者肝素使用的文献的审查.
- 对疫苗诱导的免疫血栓性血栓性缺血症 (VITT) 报告的病例和科学文献的分析.
- 对HIT和VITT的临床表现,病理生理学和管理进行比较分析.
主要成果:
- 在COVID-19患者中,治疗性氨酸的使用与更高的出血率和HIT相关.
- 在服用特定的COVID-19疫苗后,发现了一种罕见但严重的血栓并发症VITT.
- HIT和VITT都涉及免疫介导的血小板激活导致血栓形成,临床结果相似.
结论:
- 在COVID-19中广泛使用肝素需要仔细监测出血和HIT.
- VITT代表了与某些COVID-19疫苗相关的显著,尽管很少见的血栓形成风险.
- 已确立的HIT诊断和管理指南,包括使用非氨酸抗凝剂,对于VITT管理是相关的.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
01:24Disorders of Hemostasis
837
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
837
01:05Introduction to Hemostasis
7.3K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.3K
01:22Formation of the Platelet Plug
5.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
5.8K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.1K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
519
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
519